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doi:10.1016/j.jmii.2012.01.011Non-typhoid Salmonella species represent a significant cause of aortitis. Few antimicrobial
agents can be used when the patient is allergic or intolerable to cephalosporins or fluoroqui-
nolones. Here, we report a case of bacteremia and aortitis caused by Salmonella enterica sero-
type Choleraesuis. This patient was cured by initial parenteral tigecycline and subsequent oral
ciprofloxacin without surgical intervention.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Non-typhoid Salmonella species are important human
food-borne pathogens and can cause extra-intestinal
infections, such as bacteremia, septic arthritis, osteomye-
litis and mycotic aneurysms.1 Ampicillin, trimethoprim-
sulfamethoxazole, chloramphenicol, ceftriaxone andnt of Internal Medicine,
tal, No. 138, Sheng Li Road,
il.com (W.-C. Ko).
an Society of Microbiology. Publis
commons.org/licenses/by-nc-nd/ciprofloxacin have been reported to be active in vitro and
in vivo against Salmonella species.2 In developed countries,
there is increasing resistance to third-generation cephalo-
sporins and fluoroquinolones among non-typhoid Salmo-
nella isolates,3 thereby making the selection of appropriate
antimicrobial therapy more difficult. Most antibiotics that
are active in vitro cannot cure Salmonella infections, due
to poor intracellular penetration.2 New antibiotics like
tigecycline that possess good extracellular and intracellular
antibacterial activity against Salmonella isolates are
urgently needed.4e7
Tigecycline has been reported to be active in vitro
against Salmonella species and to reach significanthed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
132 H.-J. Tang et al.intracellular concentrations.4e6 A recent study comparing
the in vitro and in vivo intracellular killing effects of
tigecycline with those of ceftriaxone against clinical non-
typhoid Salmonella isolates has been published.7 Tigecy-
cline exhibited sustained intracellular killing activity and
resulted in better survival rates of mice with peritonitis due
to multidrug-resistant Salmonella isolates when compared
to ceftriaxone, suggesting a potential use of tigecycline for
human systemic Salmonella infections. However, pharma-
cokinetic evaluations of the parenteral administration of
tigecycline demonstrated low serum levels which were
regarded as insufficient to exhibit bactericidal activity
against intracellular pathogens.8,9 Here, we present a case
of Salmonella enterica serotype Choleraesuis (S Choler-
aesuis) bacteremia and infective aortitis which were cured
by initial parenteral tigecycline and subsequent long-term
oral ciprofloxacin therapy without surgical intervention.
Case report
A 65-year old, non-insulin-dependent retired farmer was
hospitalized because of fever and chills for more than two
weeks. He had a body weight of 60 kg and was well until 3
days prior to admission to a regional hospital. Parenteral
cefazolin was ineffective and intermittent fever persisted.
A general skin rash over the limbs and trunk and mild
dyspnea developed under cefazolin therapy. Blood cultures
grew S Choleraesuis resistant to ampicillin, chloramphen-
icol, and trimethoprim/sulfamethoxazole, but susceptible
to ceftriaxone and ciprofloxacin. Abdominal pain radiating
to the back and tenderness over the lower abdomen were
reported by the patient. An abdominal computed tomog-
raphy (CT) scan disclosed infrarenal infective aortitis,
a paraaortic abscess and a suspected mycotic aneurysm
(Fig. 1A). Pus obtained by CT-guided percutaneous aspira-
tion of the paraaortic abscess grew S Choleraesuis with the
same antibiogram as the blood isolate. Based on the
suspicion of a probable Salmonella mycotic aneurysm, the
patient was transferred to the emergency department
(ED) of a medical center for further evaluation and
management.
After admission, a chest film showed increased patchy
density over the bilateral lower lungs. Laboratory studiesFigure 1. (A) A computed tomography scan with contrast enhanc
the infrarenal abdominal aorta measuring 2.8 cm  3.0 cm in size w
T10-L1 (arrows). These characteristics are compatible with a par
mycotic aneurysm. After tigecycline therapy for one month (B) a
minimal fatty strands at the infra-renal portion of the abdominal arevealed leukocytosis (17,500 cells/mL), bandemia, a high
serum level of C-reactive protein (CRP, 150 mg/L) and
a high erythrocyte sedimentation rate (ESR, 120 mm/h).
Ciprofloxacin was prescribed, due to a suspected allergy to
cephalosporins. However, severe abdominal cramping and
discomfort occurred during the first infusion of cipro-
floxacin. Therefore, tigecycline was administered paren-
terally at a loading dose of 100 mg and subsequently 50 mg
every 12 hours. Because of exacerbated back pain, a spinal
magnetic resonance imaging scan was performed. The
images revealed a soft-tissue mass surrounding the aorta at
the levels of T10-L1, lumbar spondylosis with L4-L5 disc
protrusion and moderate spinal stenosis. Conservative
medical treatment was suggested by the cardiovascular
surgeon.
Blood cultures collected at the ED still grew S Choler-
aesuis. The minimal inhibitory concentration (MIC) of tige-
cycline, as determined by the broth microdilution method,
was 0.5 mg/mL. The patient’s fever abated and his clinical
symptoms resolved. Blood cultures after 5 days of tigecy-
cline therapy were negative for growth and tigecycline
treatment was continued for 28 days. The CT scan after one
month of tigecycline therapy showed obvious shrinkage of
the paraaortic abscess (Fig. 1B). Thereafter, oral cipro-
floxacin at a dose of 500 mg was given every 12 hours and
was tolerated well. After long-term antimicrobial therapy
for four months, an abdominal CT scan revealed minimal
fatty strands at the level of the infrarenal aorta (Fig. 1C).
Follow-up serum studies disclosed normalization of serum
CRP and ESR values.
Discussion
A review of the literature revealed that overall mortality
from aortitis caused by Salmonella can be as high as 60%. Of
patients treated non-surgically, 96% would die while 63% of
patients managed by a combined medical and surgical
approach would survive.10 This highlights the essential role
of surgical interventions for source control in infected aor-
titis. Traditionally, ceftriaxone and ciprofloxacin are the
standard regimens for the treatment of Salmonella infec-
tions.3,7 There has been at least one report indicative of
increasing fluoroquinolone resistance in bacteremic isolatesement revealed a mild irregular contour with wall thickening in
ith surrounding amorphous-enhanced soft-tissue mass at levels
aaortic abscess and infective aortitis, as well as a suspected
nd oral ciprofloxacin therapy for four months (C), there were
orta. No additional Paraaortic abscess was found.
Tigecycline therapy for Salmonella Choleraesuis 133of S Choleraesuis in southern Taiwan.11 In this case, cepha-
losporin allergy and gastrointestinal intolerance to cipro-
floxacin prohibited their use. Imipenem reportedly cured
two adults with relapsing infections due to ciprofloxacin-
resistant and cefotaxime-resistant Salmonella isolates,12,13
and may represent one of the treatment alternatives for
human Salmonella infections. However, there is a lack of
ex vivo or animal data supporting the use of carbapenem
therapy for invasive Salmonella infections. In such a clinical
setting, tigecycline, which is a glycylcycline that is effective
in vitro with good tissue penetration, is a potential choice
for the treatment of invasive human Salmonella infec-
tions.4,7 Tigecycline uptake is rapid and yields high concen-
trations within polymorphic neutrophils and intracellular
drug concentration is 20e30 times higher than extracellular
concentration.6 However, the use of tigecycline to treat
bacteremia is questionable for patients in whom the MICs of
the causative pathogen approach known serum tigecycline
concentrations.14
In a recent review, tigecycline was demonstrated to be
effective, safe and well tolerated in the treatment of
secondary bacteremia associated with complicated intra-
abdominal infections, skin and soft-tissue infections, and
community-acquired pneumonia. The reported cure rates
were similar to those observed for comparative standard
therapy.15 Lefort et al.16 reported the potential of tigecy-
cline therapy in a rabbit model of enterococcal endo-
carditis but there is no prior clinical experience with using
tigecycline for the treatment of vascular infections or
bacteremia caused by Salmonella. This is the first case of
Salmonella bacteremia with aortitis to be successfully
managed by initial tigecycline therapy and subsequent
ciprofloxacin therapy without surgical intervention.
Although the potential limitations of tigecycline therapy in
treating bloodstream infections must be considered, the
maximum serum level following a standard dosing of tige-
cycline in healthy subjects was 0.82 mg/mL, which was
higher than the tigecycline MIC of the etiological isolate.5
In conclusion, our clinical experience indicates that
tigecycline may be an effective treatment for bacteremia
and vascular infections caused by S Choleraesuis.
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